J Cyst Fibros . The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

[tetano]

J Cyst Fibros


. 2022 Feb 21;S1569-1993(22)00044-3.
doi: 10.1016/j.jcf.2022.02.012. Online ahead of print.
The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York


Joseph L Simonson ¹ , Christine Esposito ² , Theresa Frantzen ³ , Katherine Henthorne ⁴ , Aileen Espinal ⁵ , Serena Romano ⁶ , Ramona Ramdeo ⁷ , Jessica Trentacoste ⁸ , Donna Tsang ⁹ , Geralyn LaVecchia ¹⁰ , Robert Abdullah ¹¹ , Maria Berdella ¹² , Lynn Bonitz ¹³ , Rany Condos ¹⁴ , Andrei Constantinescu ¹⁵ , Joan K DeCelie-Germana ¹⁶ , Emily DiMango ¹⁷ , Myah Draine ¹⁸ , Tara Gimeli ¹⁹ , Robert Giusti ²⁰ , Jessenia Guzman ²¹ , Soumia Hammouda ²² , Claire Keating ²³ , Catherine Kier ²⁴ , Alison T Lennox ²⁵ , Carmen Liriano ²⁶ , Zachary Messer ²⁷ , Amy Plachta ²⁸ , Hossein Sadeghi ²⁹ , Elinor Schwind ³⁰ , Teresa Stables-Carney ³¹ , Patricia Walker ³² , Janice Wang ³³



Affiliations

• PMID: 35256307
• DOI: 10.1016/j.jcf.2022.02.012

Abstract

Background: People with cystic fibrosis (pwCF) may be at risk of complications from COVID-19 but the impact of COVID-19 on pwCF remains unknown.
Methods: We conducted a multicenter retrospective cohort study to assess the impact of the COVID-19 pandemic first wave on pwCF in the New York metropolitan area (NY) from March 1, 2020 to August 31, 2020. Objectives were to determine (1) the prevalence of COVID-19 by PCR and IgG antibody testing, (2) the clinical characteristics of COVID-19, (3) delay in routine outpatient care, and (4) the effect on anxiety and depression in pwCF.
Results: There were 26 COVID-19 cases diagnosed by PCR or antibody testing among the study cohort of 810 pwCF. The prevalence of COVID-19 by PCR (1.6%) and IgG antibody (12.2%) testing was low. 58% of cases were asymptomatic and 82% were managed at home. 8% were hospitalized and 1 person died. 89% of pwCF experienced delay in care. The prevalence of anxiety increased from 43% baseline to 58% during the pandemic (P<0.01). In post-hoc analysis, the proportion of patients with diabetes (38% versus 16%, P<0.01) and pancreatic insufficiency (96% versus 66%, P<0.01) were higher while CFTR modulator use was lower (46% versus 65%, P = 0.05) in pwCF who tested positive for COVID-19.
Conclusions: The prevalence of COVID-19 among pwCF in NY during the pandemic first wave was low and most cases were managed at home. CFTR modulators may be protective. PwCF experienced delay in routine care and increased anxiety.

Keywords: Coronavirus; Covid-19; Cystic fibrosis; SARS-CoV2.